Sanofi News | finanzen.ch

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

25.07.24	Press Release: Online availability of Sanofi’s half-year financial report for 2024 (EN, Sanofi-Aventis)
25.07.24	Press Release: Online availability of Sanofi’s half-year financial report for 2024 (GlobeNewswire)
25.07.24	Sanofi Q2 Profit Down, Sales Rise; Lifts FY24 Business EPS View (RTTNews)
25.07.24	Press Release: Sanofi Q2 - strong performance with 10% sales growth; 2024 guidance upgraded (GlobeNewswire)
25.07.24	Press Release: Sanofi Q2 - strong performance with 10% sales growth; 2024 guidance upgraded (EN, Sanofi-Aventis)
22.07.24	Sanofi: Information concerning the total number of voting rights and shares – June 2024 (GlobeNewswire)
18.07.24	Sanofi : ALTUVIIIO XTEND-Kids Phase 3 Data Transforming Severe Hemophilia A Treatment For Children (RTTNews)
17.07.24	Press Release: NEJM publishes ALTUVIIIO XTEND-Kids phase 3 data supporting its potential to transform the treatment landscape for children with severe hemophilia A (GlobeNewswire)
17.07.24	Press Release: NEJM publishes ALTUVIIIO XTEND-Kids phase 3 data supporting its potential to transform the treatment landscape for children with severe hemophilia A (EN, Sanofi-Aventis)
03.07.24	Regeneron, Sanofi: EU Approves Dupixent As First-ever Targeted Therapy For COPD Patients (RTTNews)
03.07.24	Press Release: Dupixent approved in the EU as the first-ever targeted therapy for patients with COPD (GlobeNewswire)
03.07.24	Press Release: Dupixent approved in the EU as the first-ever targeted therapy for patients with COPD (EN, Sanofi-Aventis)
28.06.24	Media Update: Frexalimab new phase 2 data showed reduction of key biomarker of nerve cell damage in relapsing MS (EN, Sanofi-Aventis)
26.06.24	Press Release: Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic esophagitis published in NEJM (GlobeNewswire)
26.06.24	Press Release: Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic esophagitis published in NEJM (EN, Sanofi-Aventis)
25.06.24	Media Update: Riliprubart one-year follow-up from phase 2 study underpin the potential as a first-in-class treatment in chronic inflammatory demyelinating polyneuropathy (EN, Sanofi-Aventis)
25.06.24	Press Release: Availability of the Q2 2024 Aide-mémoire (GlobeNewswire)
25.06.24	Press Release: Availability of the Q2 2024 Aide-mémoire (EN, Sanofi-Aventis)
21.06.24	Press Release: Audrey Duval Derveloy appointed Global Head of Corporate Affairs, member of Sanofi’s Executive Committee (EN, Sanofi-Aventis)
21.06.24	Press Release: Audrey Duval Derveloy appointed Global Head of Corporate Affairs, member of Sanofi’s Executive Committee (GlobeNewswire)
21.06.24	Press Release: ISTH: Sanofi advances leadership in hemophilia with new data for ALTUVIIIO and fitusiran (EN, Sanofi-Aventis)
21.06.24	Press Release: ISTH: Sanofi advances leadership in hemophilia with new data for ALTUVIIIO and fitusiran (GlobeNewswire)
20.06.24	Sanofi And Biovac Ink Manufacturing Partnership To Make Inactivated Polio Vaccines In Africa (RTTNews)
20.06.24	Press Release: Sanofi and Biovac spearhead polio vaccine manufacturing capabilities in Africa (GlobeNewswire)
20.06.24	Press Release: Sanofi and Biovac spearhead polio vaccine manufacturing capabilities in Africa (EN, Sanofi-Aventis)
12.06.24	Sanofi: Information concerning the total number of voting rights and shares – May 2024 (GlobeNewswire)
11.06.24	Regeneron, Sanofi Report FDA Approval Of Kevzara To Treat Active PJIA (RTTNews)
03.06.24	Press Release: ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival in combination with VRd for newly diagnosed transplant-ineligible multiple myeloma in phase 3 (EN, Sanofi-Aventis)
03.06.24	Press Release: ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival in combination with VRd for newly diagnosed transplant-ineligible multiple myeloma in phase 3 (GlobeNewswire)
01.06.24	Media Update: Sanofi update on Zantac litigation (EN, Sanofi-Aventis)
31.05.24	Sanofi Launches 2024 Employee Stock Purchase Plan - Quick Facts (RTTNews)
31.05.24	Press Release: Sanofi launches 2024 global Employee Stock Purchase Plan (EN, Sanofi-Aventis)
31.05.24	Press Release: Sanofi launches 2024 global Employee Stock Purchase Plan (GlobeNewswire)
31.05.24	Sanofi, Regeneron: Dupixent Recommended For EU Approval By CHMP To Treat COPD Patients (RTTNews)
31.05.24	Regeneron : FDA Extends Review Period For Dupixent As COPD Treatment By Three Month (RTTNews)
31.05.24	Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD (GlobeNewswire)
31.05.24	Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD (EN, Sanofi-Aventis)
31.05.24	Press Release: Update on FDA priority review of Dupixent for the treatment of COPD patients with type 2 inflammation (EN, Sanofi-Aventis)
31.05.24	Press Release: Update on FDA priority review of Dupixent for the treatment of COPD patients with type 2 inflammation (GlobeNewswire)
30.05.24	Press Release: Sanofi completes acquisition of Inhibrx, Inc. (GlobeNewswire)
30.05.24	Press Release: Sanofi completes acquisition of Inhibrx, Inc. (EN, Sanofi-Aventis)
27.05.24	Sanofi's Sarclisa Granted FDA Priority Review For Transplant-Ineligible Multiple Myeloma Treatment (RTTNews)
27.05.24	Press Release: Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible newly diagnosed multiple myeloma (EN, Sanofi-Aventis)
27.05.24	Press Release: Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible newly diagnosed multiple myeloma (GlobeNewswire)
22.05.24	Media Update: New results from rilzabrutinib phase 2 study show potential to be first advanced oral treatment for moderate-to-severe asthma (EN, Sanofi-Aventis)
21.05.24	Sanofi, OpenAI To Build AI Software To Boost Drug Development (RTTNews)
21.05.24	Sanofi, Formation Bio, OpenAI Announce AI Collaboration (RTTNews)
21.05.24	Press Release: Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration (EN, Sanofi-Aventis)
21.05.24	Press Release: Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration (GlobeNewswire)
20.05.24	Sanofi: Information concerning the total number of voting rights and shares - April 2024 (GlobeNewswire)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Zurich Insur Gr	547.60	3.13 %	K V
Logitech Intl	70.26	2.57 %	K V
Givaudan	3’919.00	1.45 %	K V
ABB	49.58	1.08 %	K V
Swiss Re	127.20	0.99 %	K V
Holcim	89.86	-0.24 %	K V
Sika	229.00	-0.35 %	K V
Swisscom	505.50	-0.49 %	K V
Nestle	75.96	-0.73 %	K V
CieFinRichemont	117.65	-0.80 %	K V

mehr

22:34		Aufschläge in New York: Dow Jones letztendlich in der Gewinnzone
17:58		Zuversicht in Frankfurt: LUS-DAX beendet die Donnerstagssitzung im Plus
17:58		Gewinne in Frankfurt: Letztendlich Pluszeichen im DAX
17:58		SDAX aktuell: SDAX zum Handelsende auf grünem Terrain
17:58		Gute Stimmung in Zürich: Anleger lassen SPI schlussendlich steigen
17:58		Börse Europa: Euro STOXX 50 letztendlich in der Gewinnzone
17:56		Novartis-Aktie fester: Novartis passt Umsatzziele nach oben an
16:17		Roche-Aktie stabil: Swissmedic genehmigt subkutane Version von Ocrevus